omation mbers - Society for Laboratory Automation and Screening
omation mbers - Society for Laboratory Automation and Screening
omation mbers - Society for Laboratory Automation and Screening
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
11:30 am Wednesday, February 4 Proteomics – In<strong>for</strong>matics Room B1<br />
Jost Vielmetter<br />
Xencor<br />
111 W. Lemon Avenue<br />
Monrovia, Cali<strong>for</strong>nia 91016<br />
jvielmet@xencor.com<br />
Protein Variation SAR Using ActivityBase<br />
87<br />
Co-Author(s)<br />
Richard Bishop<br />
Jeff Tischler<br />
Peter Cheung<br />
Protein therapeutics is a growing focus of discovery research organizations, but few in<strong>for</strong>matics solutions exist<br />
<strong>for</strong> correlating protein structure with biological activity. Here we describe the first-ever ActivityBase application<br />
to provide protein structure-activity relationship (SAR) data. Xencor’s patented Protein Design Aut<strong>omation</strong> ®<br />
technology plat<strong>for</strong>m is the basis <strong>for</strong> structure-based protein engineering of therapeutic c<strong>and</strong>idates to produce<br />
protein variants with optimized physico-chemical characteristics. These variants are registered in ActivityBase<br />
<strong>and</strong> subjected to both traditional HTS measurements, <strong>and</strong> virtual test occasions that extract the sequence<br />
variation in<strong>for</strong>mation. Amino acids that differ from the reference sequence are recorded as test results, <strong>and</strong><br />
their corresponding sequence positions as conditions. By storing both sequence variation identity <strong>and</strong> assay<br />
measurements as ActivityBase results, queries can be constructed that reveal the relationship between primary<br />
protein sequence <strong>and</strong> biological activity <strong>for</strong> any positional “condition.” This novel approach could potentially be<br />
used <strong>for</strong> the analysis of any string-based data set.<br />
12:00 pm Wednesday, February 4 Proteomics – In<strong>for</strong>matics Room B1<br />
Enal Razvi<br />
DiscoveRx Corporation<br />
42501 Albrae Street<br />
Fremont, Cali<strong>for</strong>nia 94538<br />
erazvi@earthlink.net<br />
Strategic Opportunities in High-Content <strong>Screening</strong> <strong>and</strong> Computational Proteomics<br />
We present the industry l<strong>and</strong>scape that is emerging in the computational proteomics space. This space is still in<br />
its infancy <strong>and</strong> <strong>for</strong> the most part undefined; there<strong>for</strong>e, we seek to present the market opportunity in in<strong>for</strong>matics in<br />
the drug discovery space <strong>and</strong> then extend that to an examination of the industry trends in proteomics. In addition<br />
we will focus upon the qualitative <strong>and</strong> quantitative business opportunities in the high-content screening/secondary<br />
screening space; considered by many to be the next evolutionary step in computational proteomics. We will<br />
discuss strategic drivers <strong>and</strong> how these are translating into quantitative market opportunities <strong>for</strong> the vendors in this<br />
space. This presentation will include market models that are defining the evolution of this space.<br />
PODIUM ABSTRACTS
Change language